Developer docs
API playgroundTry for free, no card

Search company profiles

Histocell SL

Full company profile

uuid00043dl

Namestring
Histocell SL
Legal namestring
Histocell, S.L.
Websiteurl
histocell.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Histocell SL is a Spanish biopharmaceutical company headquartered in Derio (Bizkaia) that develops, manufactures, and commercializes regenerative medicine products across four interconnected business units. Its core technology relies on adipose-derived adult mesenchymal stem cells and proprietary biomaterials, including the patented HC016 cell therapy platform for conditions such as acute respiratory distress syndrome and traumatic spinal cord injury, alongside an exosome manufacturing platform and 3D-printable Wharton Gel Complex bioinks. Operations are anchored by an AEMPS-authorized, GMP-certified 800 sqm manufacturing plant in Larrabetzu that supports treatment of up to 1,200 patients per year.

The company monetizes through multiple streams: clinical development and licensing of ATMPs (one-time license style for cell therapy drugs and biological medicines), GMP-grade CDMO services to pharmaceutical and biotech clients (quote-based multi-year contracts, including the REPROCELL iPSC partnership), sales of wound care medical devices led by Reoxcare (distributed via channel partner Cardiva across Spain and through international distributors in five additional countries), and direct-to-consumer e-commerce of dermocosmetics through shop.histocell.com. Pricing is quote-based for cell therapy drugs and CDMO, and per-unit for dermocosmetics.

Histocell sells primarily to hospital systems and intensive care units (Osakidetza, Osasunbida, Cruces Hospital/Biocruces Bizkaia), pharmaceutical and biotech companies (REPROCELL, Ferrer Pharmaceuticals for spinal cord injury), and indirectly to wound care and dermatology patients. It is privately held, part of the Grupo Noraybio group alongside Artinvet S.L., with corporate investors REPROCELL Inc. (TYO: 4978) and Cardiva on the cap table, and is led by CEO Julio Font and co-founder/CSO Begoña Castro. The company holds more than 50 patents in major world markets, has executed 40+ national and 9 European Framework Programme R&D projects, and employs approximately 30 multidisciplinary professionals.

Short descriptiontext

Histocell SL is a Derio, Spain-based biopharmaceutical company that develops adipose-derived stem cell therapies (HC016), wound care medical devices (Reoxcare), dermocosmetics, and GMP-grade CDMO services for pharmaceutical clients across Europe and LATAM.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDerio, Spain
HQ citystring
Derio
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine, cell therapy drugs, CDMO manufacturing services, wound healing devices, dermocosmetic products
Industry4 codes
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Medical Equipment and Supplies Manufacturing3391
  • Pharmaceutical and Medicine Manufacturing32541
SIC code4 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
  • Surgical & Medical Instruments & Apparatus3841
Product category
Regenerative Medicine Biopharmaceuticals
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Cell Therapy Drugs
TypeOne Time License
Description

Development and sale of proprietary cell therapy medicinal products including HC016 for treatment of Acute Respiratory Distress and spinal cord injury. Revenue from clinical development and eventual commercialization of ATMPs.

histocell.com
2CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing organization offering GMP-grade manufacturing services for cell therapy products, biological medicinal products (secretomes, exosomes, CAR-T drugs), and medical devices to third-party clients.

histocell.com
3Medical Devices - Wound Care
TypeHardware Sales
Description

Sale of medical device products including Reoxcare for wound healing. Distributed through channel partners across Spain and internationally.

histocell.com
4Dermo-cosmetics
TypeOne Time License
Description

Sale of dermo-cosmetic products through e-commerce including Histoessence Booster, Wharton Gel Complex, Reoxderm Liquid, and Reoxderm Cleanse.

histocell.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Standard dermocosmetic products with per-unit pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Standard shipping: €4 for Peninsula (free over 3 units), €5 for Balearic Islands (free over 3 units), €10 for Canary Islands (customs fees borne by recipient).

histocell.com
2Custom manufacturing services for pharmaceutical and biotech clients
ModelOtherBilling cadenceMulti-year contract
Notes

CDMO services and cell therapy products are quote-based with pricing negotiated per project and client requirements.

histocell.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Reoxcare
Description

Antioxidant treatment of natural ingredients for healing of chronic wounds

histocell.com
+4 more records
Core offering1 text field

Histocell is a biopharmaceutical company that develops, manufactures, and commercializes regenerative medicine products spanning four pillars: Advanced Therapy Medicinal Products (cell therapy drugs such as HC016 for ARDS and spinal cord injury plus biological drugs based on secretomes and exosomes); CDMO services providing GMP-grade contract manufacturing of cell therapy products, exosomes, secretomes, and CAR-T drugs for third-party pharma and biotech clients; wound-healing medical devices (Reoxcare) using antioxidant technology; and a dermo-cosmetic product line. Manufacturing is conducted at two AEMPS-authorized GMP facilities in Derio and Larrabetzu, Spain.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase I clinical trial completed successfully with confirmed safety and signs of efficacy for HC016 in ARDS patients
+3 more records
Product overview1 text field

Histocell SL is a biopharmaceutical company specializing in regenerative medicine with four interconnected business units: (1) Cellular and Biological Therapy Drugs including the patented HC016 cell therapy platform; (2) CDMO manufacturing services for advanced therapy medicinal products under GMP conditions; (3) Wound Healing medical devices led by the Reoxcare product line; and (4) Dermocosmetics including Histoessence Booster, Wharton Gel Complex, Reoxderm Liquid, and Reoxderm Cleanse. The company operates manufacturing facilities in Derio (Bizkaia Technology Park) and Larrabetzu, Spain.

Product and service7 records
1Cellular and Biological Therapy Drugs (ATMPs)
CategoryCell Therapy and Biological Drugs (ATMPs)
Description

Advanced Therapy Medicinal Products (ATMPs) including cell therapy drugs based on viable cells (e.g., HC016 for ARDS and acute-phase traumatic spinal cord injury) and biological medicines based on substances secreted by cells, such as secretomes and exosomes. Targeted at hospital and pharmaceutical buyers treating patients with unmet regenerative-medicine needs.

2CDMO Services
CategoryContract Development and Manufacturing Services
Description

Contract Development and Manufacturing Organization (CDMO) services providing GMP-grade manufacturing for advanced therapy medicinal products including cell therapies, exosomes, secretomes, and CAR-T drugs for third-party pharmaceutical, biotech, and iPSC clients (e.g., REPROCELL).

3Reoxcare Wound Healing Medical Device
CategoryWound Healing Medical Device
Description

Antioxidant treatment of natural ingredients for the healing of chronic wounds, manufactured at the Larrabetzu medical-device plant under EU Regulation 2017/745. Sold to hospitals and healthcare systems (e.g., Osakidetza and Osasunbidea) through the Cardiva distribution partnership and international distributors.

4Histoessence Booster
CategoryDermo-cosmetic Product
Description

Dermo-cosmetic booster product for advanced skin care. Sold direct-to-consumer via Histocell's online shop across Spain (Peninsula €4 / Balearic €5 / Canary €10 shipping, free over 3 units).

5Wharton Gel Complex (WGC)
CategoryDermo-cosmetic Product / Biomaterial
Description

Proprietary biomaterial dermo-cosmetic product and bioink foundation used in wound healing applications and 3D printable bioinks (WGC-HA) for advanced regenerative-medicine therapies.

6Reoxderm Liquid
CategoryDermo-cosmetic Product
Description

Dermo-cosmetic liquid product for skin treatment, sold direct-to-consumer via Histocell's online shop alongside other Reoxderm and Histoessence items.

7Reoxderm Cleanse
CategoryDermo-cosmetic Product
Description

Dermo-cosmetic cleansing product for skin care, sold direct-to-consumer via Histocell's online shop.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1NABIHEAL Consortium
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-09
Description

European Horizon Europe project consortium developing antimicrobial nanostructured biomaterials for complex wound healing. Consortium includes 5 SMEs and 9 academic institutions. Histocell contributes REOXCARE technology expertise.

histocell.com
2FORCE REPAIR Consortium
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-09
Description

EU-funded project developing smart multifunctional 4D printable wound dressings for chronic wounds. 14 partners from 8 EU member states. Histocell contributes Wharton Gel Complex technology and 3D printable bioinks.

histocell.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-23
Description

Japanese biotech company REPROCELL invested in Histocell to strengthen its clinical iPSC service offerings. Histocell offers GMP-grade manufacturing services for cell therapy products while REPROCELL provides StemRNA Clinical iPSC Seed Clones compliant with FDA, EMA, and PMDA standards. In October 2025, both companies achieved GMP certification for manufacturing clinical-grade iPSC Master and Working Cell Banks.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-02-08
Description

Distribution partnership for Reoxcare wound care product throughout the Spanish healthcare system. Cardiva distributes from its central warehouse in Lezama, strengthening Histocell's commercial capacity nationally.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-06-01
Description

Horizon 2020 project developing modular graft system for bone healing using granular graft material with osteogenic coating and pre-differentiated osteogenic MSCs. Histocell contributes GMP cell manufacturing expertise.

6Biocruces Bizkaia Health Research Institute
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-01
Description

Clinical trial collaboration for HC016 cell therapy drug testing in COVID-19 ARDS patients. The institute's ICU at Cruces Hospital served as the clinical trial site.

histocell.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CDMO incumbent offering large-scale GMP manufacturing for cell and gene therapies, including autologous and allogeneic processes. Overlaps directly with Histocell's CDMO service line but at vastly greater scale and geographic reach.

TypeDirect peer
Description

Scotland-based CDMO specializing in GMP manufacturing of cell therapies including iPSC-derived and mesenchymal stem cell products. Closely comparable in size, focus, and service portfolio to Histocell's CDMO business.

3Athersys
TypeEmerging player
Description

US clinical-stage cell therapy company developing MultiStem for ARDS and other inflammatory indications. Direct therapeutic area overlap with Histocell's HC016 ARDS program, though operating at later clinical stage.

TypeBroad incumbent
Description

Australia-listed commercial-stage cell therapy company with mesenchymal stem cell platforms targeting inflammatory and immune diseases, including ARDS. Comparable in modality (MSC therapies) and indication set to Histocell's pipeline.

TypeDirect peer
Description

Canadian centre of excellence offering process development, GMP manufacturing, and commercialization services for cell and gene therapies, including iPSC platforms. Highly comparable in offering mix and academic/industry positioning to Histocell.

TypeDirect peer
Description

Germany-headquartered manufacturer of GMP-grade raw materials, cytokines, and cell processing reagents for cell and gene therapy developers. Comparable to Histocell's ancillary cell processing capabilities and CDMO-adjacent product offering.

7TiGenix (Takeda)
TypeBroad incumbent
Description

Acquired by Takeda, TiGenix developed Cx601 (darvadstrocel), an approved adipose-derived stem cell therapy for complex perianal fistulas in Crohn's disease. Closely comparable adipose-derived MSC modality and wound/inflammatory indication focus to Histocell's HC016.

TypeOthers
Description

Spanish medical device distributor that is both a Histocell shareholder and exclusive Reoxcare distributor. Acts as a channel partner and strategic capital source rather than direct product competitor.

TypeDirect peer
Description

Japanese biotech (TYO: 4978) that is both an investor and active partner of Histocell, providing StemRNA Clinical iPSC Seed Clones and jointly achieving GMP certification for clinical-grade iPSC MCB/WCB. Direct overlap in GMP-grade cell therapy manufacturing and iPSC services for regenerative medicine.

TypeBroad incumbent
Description

Catalent's cell therapy manufacturing business (including MaSTherCell in Belgium) is a leading ATMP CDMO serving North American and European biotechs. Directly comparable to Histocell's CDMO offering for cell therapies and biological medicinal products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Histocell SL

Regenerative Medicine Biopharmaceuticalshistocell.com

Histocell SL is a Derio, Spain-based biopharmaceutical company that develops adipose-derived stem cell therapies (HC016), wound care medical devices (Reoxcare), dermocosmetics, and GMP-grade CDMO services for pharmaceutical clients across Europe and LATAM.

What Histocell SL does

Histocell SL is a Spanish biopharmaceutical company headquartered in Derio (Bizkaia) that develops, manufactures, and commercializes regenerative medicine products across four interconnected business units. Its core technology relies on adipose-derived adult mesenchymal stem cells and proprietary biomaterials, including the patented HC016 cell therapy platform for conditions such as acute respiratory distress syndrome and traumatic spinal cord injury, alongside an exosome manufacturing platform and 3D-printable Wharton Gel Complex bioinks. Operations are anchored by an AEMPS-authorized, GMP-certified 800 sqm manufacturing plant in Larrabetzu that supports treatment of up to 1,200 patients per year.

The company monetizes through multiple streams: clinical development and licensing of ATMPs (one-time license style for cell therapy drugs and biological medicines), GMP-grade CDMO services to pharmaceutical and biotech clients (quote-based multi-year contracts, including the REPROCELL iPSC partnership), sales of wound care medical devices led by Reoxcare (distributed via channel partner Cardiva across Spain and through international distributors in five additional countries), and direct-to-consumer e-commerce of dermocosmetics through shop.histocell.com. Pricing is quote-based for cell therapy drugs and CDMO, and per-unit for dermocosmetics.

Histocell sells primarily to hospital systems and intensive care units (Osakidetza, Osasunbida, Cruces Hospital/Biocruces Bizkaia), pharmaceutical and biotech companies (REPROCELL, Ferrer Pharmaceuticals for spinal cord injury), and indirectly to wound care and dermatology patients. It is privately held, part of the Grupo Noraybio group alongside Artinvet S.L., with corporate investors REPROCELL Inc. (TYO: 4978) and Cardiva on the cap table, and is led by CEO Julio Font and co-founder/CSO Begoña Castro. The company holds more than 50 patents in major world markets, has executed 40+ national and 9 European Framework Programme R&D projects, and employs approximately 30 multidisciplinary professionals.

Histocell SL firmographics

Firmographics
Name
Histocell SL
Legal name
Histocell, S.L.
Website
https://histocell.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Histocell SL is a Derio, Spain-based biopharmaceutical company that develops adipose-derived stem cell therapies (HC016), wound care medical devices (Reoxcare), dermocosmetics, and GMP-grade CDMO services for pharmaceutical clients across Europe and LATAM.
Ownership category
akta.pro rank

Histocell SL industry classification

Industry
Product category
Regenerative Medicine Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Regenerative medicine
  • Cell therapy drugs
  • CDMO manufacturing services
  • Wound healing devices
  • Dermocosmetic products

Where Histocell SL is headquartered

Location

Headquarters

HQ city
Derio
HQ country
Spain
HQ region
Europe

Offices3 records

Markets served

Histocell SL business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Cell Therapy Drugs: Development and sale of proprietary cell therapy medicinal products including HC016 for treatment of Acute Respiratory Distress and spinal cord injury. Revenue from clinical development and eventual commercialization of ATMPs.
  2. CDMO Services: Contract development and manufacturing organization offering GMP-grade manufacturing services for cell therapy products, biological medicinal products (secretomes, exosomes, CAR-T drugs), and medical devices to third-party clients.
  3. Medical Devices - Wound Care: Sale of medical device products including Reoxcare for wound healing. Distributed through channel partners across Spain and internationally.
  4. Dermo-cosmetics: Sale of dermo-cosmetic products through e-commerce including Histoessence Booster, Wharton Gel Complex, Reoxderm Liquid, and Reoxderm Cleanse.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard dermocosmetic products with per-unit pricing
OtherMulti-year contractCustom manufacturing services for pharmaceutical and biotech clients

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Histocell SL product offering

Product offering

Core offering

Histocell is a biopharmaceutical company that develops, manufactures, and commercializes regenerative medicine products spanning four pillars: Advanced Therapy Medicinal Products (cell therapy drugs such as HC016 for ARDS and spinal cord injury plus biological drugs based on secretomes and exosomes); CDMO services providing GMP-grade contract manufacturing of cell therapy products, exosomes, secretomes, and CAR-T drugs for third-party pharma and biotech clients; wound-healing medical devices (Reoxcare) using antioxidant technology; and a dermo-cosmetic product line. Manufacturing is conducted at two AEMPS-authorized GMP facilities in Derio and Larrabetzu, Spain.

Product overview

Histocell SL is a biopharmaceutical company specializing in regenerative medicine with four interconnected business units: (1) Cellular and Biological Therapy Drugs including the patented HC016 cell therapy platform; (2) CDMO manufacturing services for advanced therapy medicinal products under GMP conditions; (3) Wound Healing medical devices led by the Reoxcare product line; and (4) Dermocosmetics including Histoessence Booster, Wharton Gel Complex, Reoxderm Liquid, and Reoxderm Cleanse. The company operates manufacturing facilities in Derio (Bizkaia Technology Park) and Larrabetzu, Spain.

Differentiator

Problem solved

Functional benefit

Brands

  • Reoxcare: Antioxidant treatment of natural ingredients for healing of chronic wounds
  • Histoessence Booster
  • Wharton Gel Complex
  • Reoxderm Liquid
  • Reoxderm Cleanse

Products and services

  • Cellular and Biological Therapy Drugs (ATMPs) Advanced Therapy Medicinal Products (ATMPs) including cell therapy drugs based on viable cells (e.g., HC016 for ARDS and acute-phase traumatic spinal cord injury) and biological medicines based on substances secreted by cells, such as secretomes and exosomes. Targeted at hospital and pharmaceutical buyers treating patients with unmet regenerative-medicine needs.
  • CDMO Services Contract Development and Manufacturing Organization (CDMO) services providing GMP-grade manufacturing for advanced therapy medicinal products including cell therapies, exosomes, secretomes, and CAR-T drugs for third-party pharmaceutical, biotech, and iPSC clients (e.g., REPROCELL).
  • Reoxcare Wound Healing Medical Device Antioxidant treatment of natural ingredients for the healing of chronic wounds, manufactured at the Larrabetzu medical-device plant under EU Regulation 2017/745. Sold to hospitals and healthcare systems (e.g., Osakidetza and Osasunbidea) through the Cardiva distribution partnership and international distributors.
  • Histoessence Booster Dermo-cosmetic booster product for advanced skin care. Sold direct-to-consumer via Histocell's online shop across Spain (Peninsula €4 / Balearic €5 / Canary €10 shipping, free over 3 units).
  • Wharton Gel Complex (WGC) Proprietary biomaterial dermo-cosmetic product and bioink foundation used in wound healing applications and 3D printable bioinks (WGC-HA) for advanced regenerative-medicine therapies.
  • Reoxderm Liquid Dermo-cosmetic liquid product for skin treatment, sold direct-to-consumer via Histocell's online shop alongside other Reoxderm and Histoessence items.
  • Reoxderm Cleanse Dermo-cosmetic cleansing product for skin care, sold direct-to-consumer via Histocell's online shop.

Quantifiable outcome

  • Phase I clinical trial completed successfully with confirmed safety and signs of efficacy for HC016 in ARDS patients
  • +3 more outcomes

Companies that use Histocell SL

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Histocell SL technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Histocell SL partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • NABIHEAL ConsortiumminorStrategic or Co-development Partner · 9 January 2023European Horizon Europe project consortium developing antimicrobial nanostructured biomaterials for complex wound healing. Consortium includes 5 SMEs and 9 academic institutions. Histocell contributes REOXCARE technology expertise.
  • FORCE REPAIR ConsortiumminorStrategic or Co-development Partner · 9 January 2023EU-funded project developing smart multifunctional 4D printable wound dressings for chronic wounds. 14 partners from 8 EU member states. Histocell contributes Wharton Gel Complex technology and 3D printable bioinks.
  • REPROCELL Inc.coreStrategic or Co-development Partner · 23 November 2022Japanese biotech company REPROCELL invested in Histocell to strengthen its clinical iPSC service offerings. Histocell offers GMP-grade manufacturing services for cell therapy products while REPROCELL provides StemRNA Clinical iPSC Seed Clones compliant with FDA, EMA, and PMDA standards. In October 2025, both companies achieved GMP certification for manufacturing clinical-grade iPSC Master and Working Cell Banks.
  • CardivacoreChannel Partner/ Reseller/ Distributor · 8 February 2021Distribution partnership for Reoxcare wound care product throughout the Spanish healthcare system. Cardiva distributes from its central warehouse in Lezama, strengthening Histocell's commercial capacity nationally.
  • HEALIKICK ConsortiumminorStrategic or Co-development Partner · 1 June 2020Horizon 2020 project developing modular graft system for bone healing using granular graft material with osteogenic coating and pre-differentiated osteogenic MSCs. Histocell contributes GMP cell manufacturing expertise.
  • Biocruces Bizkaia Health Research InstitutecoreStrategic or Co-development Partner · 1 May 2020Clinical trial collaboration for HC016 cell therapy drug testing in COVID-19 ARDS patients. The institute's ICU at Cruces Hospital served as the clinical trial site.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Histocell SL competitors and assessment

Company assessment

Broad incumbents

  • Lonza Cell & Gene Technologies: Global CDMO incumbent offering large-scale GMP manufacturing for cell and gene therapies, including autologous and allogeneic processes. Overlaps directly with Histocell's CDMO service line but at vastly greater scale and geographic reach.
  • Mesoblast: Australia-listed commercial-stage cell therapy company with mesenchymal stem cell platforms targeting inflammatory and immune diseases, including ARDS. Comparable in modality (MSC therapies) and indication set to Histocell's pipeline.
  • TiGenix (Takeda): Acquired by Takeda, TiGenix developed Cx601 (darvadstrocel), an approved adipose-derived stem cell therapy for complex perianal fistulas in Crohn's disease. Closely comparable adipose-derived MSC modality and wound/inflammatory indication focus to Histocell's HC016.
  • Catalent (MaSTherCell): Catalent's cell therapy manufacturing business (including MaSTherCell in Belgium) is a leading ATMP CDMO serving North American and European biotechs. Directly comparable to Histocell's CDMO offering for cell therapies and biological medicinal products.

Direct peers

  • RoslinCT: Scotland-based CDMO specializing in GMP manufacturing of cell therapies including iPSC-derived and mesenchymal stem cell products. Closely comparable in size, focus, and service portfolio to Histocell's CDMO business.
  • CCRM: Canadian centre of excellence offering process development, GMP manufacturing, and commercialization services for cell and gene therapies, including iPSC platforms. Highly comparable in offering mix and academic/industry positioning to Histocell.
  • CellGenix: Germany-headquartered manufacturer of GMP-grade raw materials, cytokines, and cell processing reagents for cell and gene therapy developers. Comparable to Histocell's ancillary cell processing capabilities and CDMO-adjacent product offering.
  • REPROCELL: Japanese biotech (TYO: 4978) that is both an investor and active partner of Histocell, providing StemRNA Clinical iPSC Seed Clones and jointly achieving GMP certification for clinical-grade iPSC MCB/WCB. Direct overlap in GMP-grade cell therapy manufacturing and iPSC services for regenerative medicine.

Emerging players

  • Athersys: US clinical-stage cell therapy company developing MultiStem for ARDS and other inflammatory indications. Direct therapeutic area overlap with Histocell's HC016 ARDS program, though operating at later clinical stage.

Others

  • Cardiva: Spanish medical device distributor that is both a Histocell shareholder and exclusive Reoxcare distributor. Acts as a channel partner and strategic capital source rather than direct product competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Histocell SL compliance and trust

Trust signal

Compliance6 records

Histocell SL financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Histocell SL leadership team

Management profile

Number of profiles

Profiles5 records

Histocell SL funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Histocell SL M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Histocell SL

What does Histocell SL do?

Histocell is a biopharmaceutical company that develops, manufactures, and commercializes regenerative medicine products spanning four pillars: Advanced Therapy Medicinal Products (cell therapy drugs such as HC016 for ARDS and spinal cord injury plus biological drugs based on secretomes and exosomes); CDMO services providing GMP-grade contract manufacturing of cell therapy products, exosomes, secretomes, and CAR-T drugs for third-party pharma and biotech clients; wound-healing medical devices (Reoxcare) using antioxidant technology; and a dermo-cosmetic product line. Manufacturing is conducted at two AEMPS-authorized GMP facilities in Derio and Larrabetzu, Spain.

Is Histocell SL a public or private company?

Histocell SL is a private company. It is classified as unknown and is currently operating.

When was Histocell SL founded?

Histocell SL was founded in 2006. It employs 11 to 50 people.

Where is Histocell SL based?

Histocell SL is headquartered in Derio, Spain, in the Europe region.

How does Histocell SL make money?

Four revenue lines are on record. Cell Therapy Drugs are the primary driver. The others are CDMO Services, medical Devices - Wound Care and dermo-cosmetics.

Who are Histocell SL's main competitors?

Broad incumbents on record are Lonza Cell & Gene Technologies, Mesoblast, TiGenix (Takeda) and Catalent (MaSTherCell). Direct peers are RoslinCT, CCRM, CellGenix and REPROCELL. Athersys is listed as an emerging player. Cardiva is listed as an others.

Does Histocell SL have an API?

No public API is recorded for Histocell SL.

What industry is Histocell SL in?

Histocell SL's product category is Regenerative Medicine Biopharmaceuticals. Its primary akta.pro industry code is HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing), with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales